Testosterone dosage

Protocol

1. 1

   Reconstitute the vial

   Reconstitute the lyophilized vial with bacteriostatic water. The resulting concentration determines your syringe units per dose.

   Open tool →
2. 2

   Measure the dose

   Typical Testosterone dose is 150 mg. Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet). Half-life of 192 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Medical TRT is not cycled; non-medical performance protocols sometimes cycle alongside other agents (outside this framing)

   Open tool →
5. 5

   Monitor for side effects

   Watch for: erythrocytosis; acne; oily skin; fluid retention. Stop or reduce dose if tolerability breaks down.

Why this dose

Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects.

The typical 150 mg dose is the figure most commonly used in published protocols for Testosterone. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

Testosterone is administered via the intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 24 hours after administration. Peak effect lands near 3 days post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Free testosterone half-life only minutes; ester half-lives drive clinical PK: cypionate ~8 days, enanthate ~7 days, propionate ~2 days, undecanoate (oral) shorter

Cycling and tolerance

Medical TRT is not cycled; non-medical performance protocols sometimes cycle alongside other agents (outside this framing)

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
• Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
• TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
• Schedule III controlled substance in US; WADA banned in sport
• Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
• Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect

Side effects and interactions

Common side effects

• erythrocytosis
• acne
• oily skin
• fluid retention
• increased body hair

Notable interactions

• warfarin (moderate): may potentiate anticoagulant effect; monitor INR
• insulin (moderate): may improve insulin sensitivity; monitor glucose in diabetics
• 5-alpha reductase inhibitors (finasteride) (moderate): blocks DHT conversion; reduces some androgen effects
• aromatase inhibitors (anastrozole) (moderate): lowers estradiol; risk of over-suppression

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Testosterone profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Schedule III

Pregnancy

Category X; contraindicated in pregnancy (virilizing effect on female fetus)

Legal status

Schedule III controlled substance (US); WADA banned

Do not use if

• active prostate cancer
• active breast cancer
• untreated severe sleep apnea
• untreated severe BPH
• uncontrolled heart failure
• polycythemia at baseline

Related research